MAIA initiates Phase 3 trial, secures FDA Fast Track, raises $33M; crypto strategy announced then shelved

Filed March 23, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 21, 2025 · ~2 min read

Key Changes

• high

  Company initiated Phase 3 pivotal trial (THIO-104) in 2025, randomizing up to 300 third-line NSCLC patients 1:1 against chemotherapy—a direct path toward potential regulatory approval and the company's first registration-stage study.

  MD&A: Phase 3 Trial verify on EDGAR →
• high

  FDA granted Fast Track designation for ateganosine in July 2025, enabling more frequent agency interactions and potential expedited review; NIH awarded $2.3M grant for Phase 2 expansion, providing non-dilutive funding.

  Business: FDA Fast Track & NIH Grant verify on EDGAR →
• high

  March 2026 underwritten offering raised $33M gross proceeds at $1.50/share (22M shares), substantially strengthening balance sheet; auditor removed prior-year going-concern opinion despite accumulated deficit growing to $109.6M.

  MD&A: Capital Raise & Risk Factors: Going Concern verify on EDGAR →